Italian biopharmaceutical company Kedrion is exploring a debt package of roughly $2 billion, with the proceeds potentially being used to fund a large dividend to shareholders.
The proposal highlights a broader trend in private healthcare: companies with relatively stable, cash-generating businesses can use additional leverage to return capital to their owners.
But there is an obvious question investors should ask:
Why borrow billions to pay a dividend instead of using that money to reduce debt or invest in the business?
Kedrion Has Been Growing
Kedrion’s underlying business has been performing well.
The company reported €1.65 billion in revenue for 2025, up 4.5% from the previous year. Adjusted EBITDA rose 22.6% to €341.4 million, marking its fourth consecutive year of double-digit EBITDA growth.
That gives management a reasonable argument for taking on additional debt.
The company is generating more operating cash and has a business focused on plasma-derived therapies, a relatively specialized healthcare market.
But Debt Is Already Significant
The problem is that Kedrion is not starting from a clean balance sheet.
At the end of 2025, the group reported a net financial position of €853.3 million, despite reducing it by about €92.5 million during the year.
Adding roughly $2 billion of new borrowing would therefore represent a meaningful increase in leverage.
The key question becomes whether future cash generation can comfortably service the additional interest burden.
Why Fund a Dividend With Debt?
There are several reasons shareholders might favor this structure.
Returning Capital
Private-equity owners can use debt to extract cash without selling the company.
Tax Efficiency
Depending on the financing structure and jurisdiction, interest expenses can provide tax benefits that dividends do not.
Maintaining Ownership
Borrowing allows existing shareholders to receive cash while retaining their equity stake.
Confidence in Future Cash Flow
Management may believe Kedrion’s recurring cash generation is strong enough to support higher leverage.
But these benefits come with a cost.
The dividend does not make the company more valuable by itself. It simply moves cash from the company to its owners while leaving the company with more debt.
The Plasma Business Is Attractive — But Not Risk-Free
Kedrion operates in plasma-derived medicines, including treatments for rare and ultra-rare diseases.
The company has also been expanding in the US. Its QIVIGY product entered the US market in February 2026 after FDA approval.
That expansion could support future revenue growth.
However, the plasma industry has a structural constraint: access to plasma.
Kedrion itself has previously warned that geopolitical disruptions can interfere with the delivery of plasma-derived medicines. During the Middle East conflict, the company warned that supply disruptions could affect deliveries to Iran.
So the company’s cash flows may be resilient, but they are not immune to supply-chain shocks.
The US Market Is Becoming More Important
Kedrion’s growth strategy increasingly involves the United States.
The company’s 2025 report notes the launch of QIVIGY in the US in February 2026, with an initial sale worth approximately $10.1 million.
If the company can expand its US commercial footprint, that could provide an additional source of growth capable of supporting the higher debt load.
But that growth needs to materialize.
Borrowing today against expected future growth creates more risk than borrowing against already-established cash flow.
The Biggest Issue Is Leverage
The headline $2 billion figure sounds large because it is.
Compared with 2025 adjusted EBITDA of €341.4 million, a $2 billion debt raise would be several times annual EBITDA on its own, before considering existing financial obligations.
That doesn’t automatically make the transaction dangerous.
Plasma-derived medicines can produce relatively predictable demand.
But leverage becomes uncomfortable when growth slows.
For example:
Higher debt → higher interest expense → less free cash flow → less money for investment → greater sensitivity to downturns.
That is the trade-off shareholders are effectively accepting in exchange for the dividend.
Why Private Owners May Like the Deal
The incentives are different for a financial sponsor than for a long-term operating company.
A sponsor may prefer:
Debt-funded dividend → immediate cash return → retain ownership → potentially sell the company later.
From the shareholder’s perspective, this can improve the return on invested capital.
But from the company’s perspective, the balance sheet becomes weaker.
That distinction matters.
A debt-funded dividend can be perfectly rational for owners while simultaneously increasing financial risk for the operating business.
Kedrion’s Growth Gives It Some Cushion
The strongest argument in favor of the transaction is the company’s recent earnings trajectory.
Revenue has grown consistently, while EBITDA has grown much faster than revenue. Kedrion reported four consecutive years of double-digit EBITDA growth through 2025.
If that continues, the company could deleverage naturally through earnings and cash generation.
But investors shouldn’t assume that four years of strong EBITDA growth guarantees another four years.
Healthcare businesses still face:
- Regulatory risk
- Pricing pressure
- Plasma collection constraints
- Manufacturing costs
- Currency movements
- Geopolitical disruptions
- Product concentration risk
What Could Go Wrong?
The main risks are straightforward.
Earnings Slow
If EBITDA growth falls sharply, debt-service coverage deteriorates.
Interest Costs Rise
Refinancing could become expensive if credit markets tighten.
Plasma Supply Is Disrupted
Shortages could limit production and increase costs.
US Expansion Disappoints
If new products fail to scale, expected future cash flow may not arrive.
Acquisition or Investment Capacity Falls
A large dividend leaves less flexibility for strategic investment.
What Investors Should Watch
The most important numbers will be:
Net debt / EBITDA
Interest coverage
Free cash flow
Debt maturity schedule
Interest rate on the new financing
Dividend size
Use of proceeds
US revenue growth
Plasma collection volumes
Those will tell us whether the transaction is simply an aggressive but manageable recapitalization or an excessive increase in leverage.
The Bigger Picture
Kedrion’s reported operating performance gives it a credible case for additional borrowing: revenue reached €1.65 billion in 2025 and adjusted EBITDA climbed to €341.4 million.
But the proposed transaction should not automatically be interpreted as a sign that the company is flush with excess cash.
Borrowing $2 billion to pay shareholders is fundamentally a capital-allocation decision, not an operational investment.
The deal could make sense if Kedrion’s cash flows are highly predictable and management believes the business is underleveraged.
It becomes much less attractive if the company is using debt because organic cash generation is insufficient to support the desired shareholder payout.
The critical question is therefore not “Can Kedrion afford a $2 billion debt raise today?”
It is:
“Can Kedrion comfortably carry that debt if growth, plasma supply or healthcare markets become less favorable?”
That is what the eventual financing terms and leverage ratios will reveal.
